Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy.


BACKGROUND. Some of the most important questions relating to the use of biological therapy in inflammatory bowel diseases concern the duration of maintenance therapy. The RASH study revealed that previous use of biological therapy and dose intensification are associated with restarting of biological therapy in Crohn's disease. The aim of the study was to… (More)
DOI: 10.3109/00365521.2013.845906


  • Presentations referencing similar topics